Background {#Sec1}
==========

Individuals infected with HIV-1 exhibit changes in serum lipid levels seen as hypercholesterolemia and hypertriglyceridemia \[[@CR1]--[@CR4]\]. Following antiretroviral therapy (ART), lipid levels remain skewed for many patients, as LDL-cholesterol (LDL-C) and triglycerides increase while HDL-cholesterol (HDL-C) remains lowered \[[@CR1]--[@CR3], [@CR5]--[@CR7]\].

Previous studies have shown that this dyslipidemic profile is associated with greater risk for cardiovascular disease (CVD), myocardial infarction and atherosclerosis in HIV-positive individuals \[[@CR3], [@CR5], [@CR8]--[@CR11]\]. As some in the HIV-1 infected population have begun to reach the age where CVD risk is increased and the affect of HIV infection on this risk in unknown, there is a need to understand the mechanisms behind therapy-associated lipid dysfunction. Many factors likely contribute towards this dyslipidemia, including the different drug components used in ART \[[@CR12]--[@CR14]\] as well as factors innate to the individual. The prevalence of dyslipidemia is high, but not all-inclusive, among the HIV-positive population suggesting that genetic factors potentially have a role \[[@CR15]\]. Studies have already illustrated a broad genetic impact on lipids, as lipid levels and CVD risk vary based on ethnic background in HIV uninfected populations \[[@CR16]--[@CR18]\]. We have recently shown that biogeographical ancestry was significantly associated with lipid levels in a cohort of men who have sex with men (MSM), and that European ancestry results in a more atherogenic phenotype even after controlling for HIV and therapy components \[[@CR19]\].

Furthermore, several genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) associated with CVD risk \[[@CR20]--[@CR25]\], many of which are present in genes involved in cholesterol metabolism and transport. One particularly relevant set of genes is that of the reverse cholesterol transport (RCT) pathway, which directly influences lipid levels. Polymorphisms in genes of this pathway, and in those directly interacting with it, contribute to the variance of lipid levels, and also alter expression levels of some of the genes themselves \[[@CR15], [@CR26]--[@CR33]\]. Recent studies have identified specific mutations located within RCT genes that are associated with altered lipid levels in individuals with HIV-associated atherogenic dyslipidemia. The SNP rs3135506, located in the *APOA5* gene, was associated with increased triglycerides and decreased HDL-C, while a SNP in the *LPL* gene, rs328, was associated with increased levels of HDL-C \[[@CR34]\]. Additionally, common SNP genotypes in *APOE* were found to be associated with lipid levels where the E2 allele has a protective effect against dyslipidemia while the E4 is indicative of more risk \[[@CR35]\]. Furthermore, expression levels of *LDLR* can be modified by mutations in the proprotein-convertase subtilisin-kexin type 9 gene (*PSCK9)*, ultimately resulting in altered levels of LDL-C \[[@CR27], [@CR36], [@CR37]\]. Individuals with loss of function mutations in *PCSK9* show decreased amounts of LDL-C while those with gain of function mutations have increased amounts \[[@CR26], [@CR33], [@CR38]\].

In addition to posttranslational protein regulation such as that seen with *PCSK9*, protein levels of RCT gene products could also be influenced by copy number variation (CNV). This type of genetic variation includes duplications, deletions, and inversions of DNA segments greater than 50 bp in size \[[@CR39]--[@CR42]\]. Previous studies on CNV in the *CCL3L1* and *DEFB4* genes illustrate that an increase in transcriptionally available copies of a gene not only results in increased expression levels but also increases in protein levels directly proportional to the number of copies \[[@CR43]--[@CR46]\]. Such variation in one or a few RCT genes has the potential to alter the functionality of this lipid metabolism pathway dramatically, and thereby influence serum HDL and LDL levels. Yet, while there have been a number of studies investigating the association of SNPs within these genes to lipid levels \[[@CR28]--[@CR32], [@CR47]\], little has been documented related to their CNV, apart from reports on rare structural variation in the *LDLR* gene associated with Familial Hypercholesterolaemia \[[@CR48]--[@CR51]\] and the occasional reported variant in *LPL*, *ABCA1*, and *LIPC* \[[@CR48], [@CR52]\]. Furthermore, the Database of Genomic Variants, a compilation of structural variation in healthy control sample genomes, contains rare CNV encompassing the RCT genes \[[@CR53]\].

Here, we designed a study employing custom Multiplex Ligation-dependent Probe Amplification (MLPA) and NanoString probes to screen for CNV in 16 RCT associated genes in participants from the Multicenter AIDS Cohort Study (MACS), to identify if CNV is present, the degree to which it varies, and whether it has an association with the abnormal lipid metabolism observed in HIV-positive individuals undergoing antiretroviral therapy.

Results {#Sec2}
=======

Sample demographics {#Sec3}
-------------------

Using the 2005 clinic measurements, and the NCEP/ATP III report criteria \[[@CR54]\] (HDL-C ≤40 mg/dL or ≥60 mg/dL; LDL-C ≤100 mg/dL or ≥130 mg/dL), 366 suitable MACS participants were identified, of which 319 were successfully analyzed using MLPA (Fig. [1](#Fig1){ref-type="fig"}). The demographic data for these 319 samples are summarized in Table [1](#Tab1){ref-type="table"}. We identified 23 samples with an atheroprotective phenotype (HDL-C ≥60 mg/dL and LDL-C ≤100 mg/dL) and 7 samples with an atherogenic phenotype (HDL-C ≤40 mg/dL and LDL-C ≥160 mg/dL). Those with the atherogenic lipid profile had a higher mean body mass index (BMI), plus higher total cholesterol and triglyceride levels when compared to those who had the atheroprotective phenotype. Age among all lipid groups was similar, with a median age of 48 (IQR: 47--49). BMI was higher in the uninfected individuals within each grouping and, with the exception of the atheroprotective group, the mean BMI of most groups ranged from overweight to borderline obese.Fig. 1Sample Subset Selection Methodology. Samples were initially selected on the basis of DNA quality. HDL and LDL measurements were then used to identify atheroprotective and atherogenic subgroups, and control samples with HDL and LDL values in the normal range were selected to complete the sample setTable 1Demographic and descriptive characteristics of study participantsHDL ≤ 40 mg/dLHDL = 40--60 mg/dLLDL≤100 mg/dL100-130 mg/dL130--160 mg/dL≥160 mg/dLLDL Not Measured≤100 mg/dL100--130 mg/dL130--160 mg/dLHIV StatusHIV−HIV+HIV−HIV+HIV−HIV+HIV−HIV+HIV−HIV+HIV−HIV+HIV−HIV+HIV−HIV+n174612271973417231519111712*Median*Age (years)5148.5534845554046.55646484650504846BMI31.625.227.825.22823.927.530.230.623.427.124.726.424.826.924.2HDL (mg/dL)3429.134.53136343735.92828.65048.250485146.7LDL (mg/dL)7878.5121115145142172175130--7686112110145140TCHOL (mg/dL)153143189188213214241253181182146151185187215225TRIG (mg/dL)20319720522515215613214811443481102110108101178*\# on therapy*No therapy--12--9--2--1--2--3------2Mono-therapy------------------------1----Combination--5--1----------------------Potent ART--29--17--5--3--5--12--10--10*Therapy adherence*100 %--10--7--3--2------3--4--595--99 %--19--8--2--1--5--8--6--4\<75 %--3--2------------1------1NA--14--10--2--1--2--3--1--2*BGA*AEA--4354----1----637212AsEA12--------------1--------21EA153982215733161612129149NA111--------------1----------Group total174612271973417231519111712HDL = 40--60 mg/dLHDL ≥ 60 mg/dLLDL≥160 mg/dLLDL not measured≤100 mg/dL100--130 mg/dL130--160 mg/dL≥160 mg/dLLDL not measuredHIV StatusHIV−HIV+HIV−HIV+HIV−HIV+HIV−HIV+HIV−HIV+HIV−HIV+HIV−HIV+n1341181587263614*Median*Age (years)50492252454246.55253.54759473145.5BMI27.826.220.727.425.722.924.823.927.322.626.622.522.724.7HDL (mg/dL)514554.640.673.576.163.375.964.382.462.568.56071.8LDL (mg/dL)165175----92.580119111138144167167130--TCHOL (mg/dL)245251163176181181203205223249247259224236TRIG (mg/dL)134122----861031049410110210598168525*\# on therapy*No therapy----------4--1--2--2----Mono-therapy----------------------------Combination----------2----------------Potent ART--4--1--9--6--4--4--4*Therapy adherence*100 %--2------5--1------3--295--99 %--2------3--4--2----2\<75 %------1--3--1--2--1----NA----------4--1--2--2----*BGA*AEA3--1--1113----4------1AsEA--------13--------------1EA104--16157223512NA----------------------1----Group total1341181587263614^BMI,\ body\ mass\ index;\ HDL-C,\ high\ density\ lipoprotein\ cholesterol;\ LDL-C,\ low\ density\ lipoprotein\ cholesterol;\ TCHOL,\ total\ cholesterol;\ TRIG,\ triglycerides;\ monotherapy,\ single\ nucleoside\ reverse\ transcriptase\ inhibitor;\ Combination,\ two\ or\ more\ nucleoside\ reverse\ transcriptase\ inhibitors;\ potent\ ART,\ two\ or\ more\ nucleoside\ reverse\ transcriptase\ inhibitors\ with\ a\ protease\ inhibitor\ or\ a\ nonnucleoside\ reverse\ transcriptase\ inhibitor;\ BGA,\ biogeographical\ ancestry;\ AEA,\ African/European\ ancestry;\ EA,\ European\ ancestry;\ AsEA,\ Asian\ European\ ancestry^

Of the individuals who were HIV-positive during 2005, over 70 % were receiving a type of antiretroviral therapy (Potent ART, combination, or monotherapy defined according to the DHHS/Kaiser panel criteria \[[@CR55]\]). Of those who reported therapy use, around three quarters had over 95 % self-reported adherence. We also compared the distribution of Biogeographical Ancestry (BGA), recently determined for these samples \[[@CR19]\], for the sample subset. The majority of samples in each group were those of European ancestry, followed by those of mixed African-European ancestry, and a few samples with Asian-European ancestry. However in the HIV-positive groups with high HDL-C (≥60 mg/dL) and in the atheroprotective group, samples with African-European ancestry were in the majority.

Multiplex ligation dependent probe amplification {#Sec4}
------------------------------------------------

As reference samples with known copies of the RCT genes are not available, we identified experimental samples whose normalized peak height for each probe was similar to the sample set mean height. Using these samples as references, the coffalyser.net software calculated the probe ratios for each sample relative to the reference samples. Assuming that the most frequently observed ratio corresponded to two copies per diploid genome, ratios above 0.7 and below 1.3 are considered to be within the normal range of two copies \[[@CR56]\]. Anything outside of these arbitrary MRC-Holland derived thresholds was identified as an outlier with potential CNV.

Of the 16 RCT pathway associated genes screened, only three (*APOA4*, *CETP*, and *ABCA1*) showed any signs of CNV, and in each case the CNV was extremely rare. For each of these genes, a few individuals showed ratios that crossed or were at the lower threshold (Fig. [2](#Fig2){ref-type="fig"}). None of the RCT genes had CNV ratios that passed the upper ratio bound of 1.3, suggesting that no sample showed gains in copy number. Table [2](#Tab2){ref-type="table"} lists normalized ratios of the three genes for samples with losses along with the sample's 2005 visit HDL-C and LDL-C levels.Fig. 2Copy number variation is exceedingly rare for reverse cholesterol transport pathway genes. Copy number ratios are shown for the four individuals that had detectable CNV. Probes representing the RCT genes are on the left of the figure while reference probes (Ref_1--Ref_16), ligation controls (Ref_18), and denaturation controls (Ref_17, Ref_19) are on the right. The dots show the copy number ratios of each probe for each individual. The *box plots* represent the 95 % confidence interval of each probe ratio derived from the entire sample set. Arbitrary thresholds at 1.3 and 0.7 are represented by the *dotted horizontal lines*. Points that fall within these thresholds are considered to have a copy number ratio of 1.0Table 2Normalized ratios of reverse cholesterol transport pathway gene CNV probes that showed significant departure from unityLipid levels^a^Normalized ratios^b^SampleLDL-C, mg/dLHDL-C, mg/dLABCA1APOA4CETPSRBI123147 (132.25--162.25)55 (51--68.3)10.56\*0.991.06157114 (103--129)30 (24.8--38.1)0.750.980.65\*0.98209136.5 (124.25--148.5)38 (36--40.4)0.7\*1.120.920.7736769 (49--76)39.2 (35.8--54.1)0.950.55\*0.931.0^a^The first two columns list median serum HDL-C and LDL-C levels from a minimum of 8 visits for that individual. Within the brackets is the IQR range for those lipid levels^b^Probes that crossed or were on the 0.7 ratio threshold are indicated with (\*)

Two samples (123 and 367) had a loss of *APOA4* copy number (with normalized ratios of 0.56 and 0.55, respectively) while sample 157 had a loss of *CETP* copy number with a ratio of 0.65. Sample 209 had a normalized ratio for *ABCA1* that fell on the 0.7 threshold indicating a possible loss. The standard deviations for each of these outlying probes were relatively small (\<±0.05) indicating that the decrease in ratio observed was likely genuine. When MLPA was performed for a second time on these 4 samples, the observations were consistent with the first run. No clear association between any of these losses and lipid levels (Table [2](#Tab2){ref-type="table"}) was apparent, although this observation is not conclusive due to the small number of samples involved.

The interquartile ranges (IQR) for most of the RCT gene probes were narrow (0.04--0.09), and similar to those of the two-copy reference probes. This tight clustering of ratios around the mean of each probe further suggests that CNV is not common in the RCT genes. The only probes with wider IQRs were *ABCA1* and *SRBI*. While their IQRs were slightly broader than the other RCT probes, this spread of the ratio distribution was also seen in the properly functioning reference probes suggesting that this was within the normal range of our experiment (data not shown).

As gold standard referents containing known copy numbers of each RCT gene are not available, and the P300 reference probe set provided by MRC-Holland includes probes with a maximum number of two copies, we developed a quality control assay to ensure that our MLPA protocol was capable of picking up a range of CNV above 2 copies (Additional file [1](#MOESM1){ref-type="media"}: Supplementary Methods). Through use of control samples with known amounts of CNV, the MRC-Holland P139 Defensin MLPA assay, and our P300/RCT assay extended to include probes for variants in the *DEFB103A* and *CCR5* genes, we were able to verify that our assay can identify a range of CNV even when the sample mean is used to define a referent (Additional file [2](#MOESM2){ref-type="media"}: Figure S2).

To determine whether the rare loss for the three RCT genes identified during MLPA reflected true CNV or problems with probe binding, Sanger sequencing was performed to examine the probe binding site for those individuals who showed losses, plus several control individuals who showed no changes in copy number. We determined that individuals who showed a loss in signal for *APOA4* were heterozygous for a rare intronic SNP rs185210669, located 1 base from the internal ligation site for that probe. This mutant allele fails to bind the left MLPA probe oligo strongly, leading to impaired ligation to the right oligo and decreased MLPA signal. The other genes (*ABCA1* and *CETP*) contained no SNPs within their ligation sites.

CNV confirmation by NanoString {#Sec5}
------------------------------

We confirmed our findings by using a custom NanoString assay to measure CNV of the RCT genes for 267 of the samples analyzed by MLPA. The CNV ratios generated mirrored those seen with MLPA (data not shown). We replicated the loss in copy number of *CETP* in sample 157 (copy number ratio of 0.58) but did not observe the losses for *ABCA1* in sample 209 (1.06) or *APOA4* for both samples 123 and 367 (1.10 and 1.04). As the MLPA-derived ratio for *ABCA1* in sample 209 fell on the threshold value of 0.7, it is likely that this sample does not in fact have a true loss in copies. It is also possible that MLPA probe used for *ABCA1* is picking up a rare small CNV that is not detected by the NanoString probe, as the probes for these assays bind in different regions of the gene. The loss observed in *APOA4* only by MLPA is attributed to the ligation-site SNP identified in the MLPA probe.

Expression analysis {#Sec6}
-------------------

We also determined the expression levels of the RCT genes in our study, using data extracted from a whole-genome transcription dataset obtained using the Illumina HT-12 platform. Gene expression levels on 127 samples were compared to both MLPA and NanoString CNV ratios. As expected, comparisons of MLPA- and NanoString-generated CNV ratios to log transformed mRNA expression levels yielded no significant associations (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Expression levels of RCT genes. Normalized copy number ratios obtained by MLPA and NanoString are plotted on the *x*-axis while log transformed mRNA expression levels are plotted on the *y*-axis. If expression level data were available for multiple splice variants of the same gene, they were each plotted against their available CNV ratios, with the different variants represented by "\_\#" following the gene name. Data are shown for the 127 individuals for whom both CNV and expression data were available

Discussion {#Sec7}
==========

The contribution of host genetic variation to the development of the CVD-associated side effects seen in response to antiretroviral therapy is still not fully understood. We have previously studied the roles of Biogeographical Ancestry \[[@CR19]\], and of individual SNPs on this, but no studies have been done to date on the impact of quantitative genetic variation such as CNV on this process. To address this, we developed an MLPA assay, and used it to measure CNV in genes within the RCT pathway \[[@CR28], [@CR29]\]. As extreme HDL and LDL abnormalities are observed in only a subset of HIV-positive patients receiving anti-retroviral therapy and experiencing dyslipidemia \[[@CR15]\], the susceptibility to these severe lipoprotein changes is likely to have a genetic component.

While previous studies have already found an association between sequence variation in genes within, and influencing, the RCT pathway and lipoprotein levels, we theorized that CNV in the RCT pathway could play a role in these extreme lipoprotein phenotypes. A region of duplication encompassing an entire gene and its regulatory regions has the capability to alter expression and protein levels in a manner directly proportional to the amount of copies present. Such a relationship is observed for the *CCL3L1* and *DEFB4* genes, where increases in gene products correspond to copies present for each gene up to a plateau point \[[@CR43], [@CR46]\]. Even though this type of variation has the potential to influence lipid metabolism, the available information on whole gene CNV in the genes of the RCT pathway is limited to a few select genes (*LDLR*, *LPL*, *ABCA1*, and *LIPC*) \[[@CR48], [@CR52]\].

Data currently available within the Database of Genomic Variants \[[@CR57]\] shows a limited amount of rare CNV present for the RCT genes. The documented CNV that is there consists primarily of insertions and deletions within the genes, rather than whole gene variation. Thus, it is unlikely that CNV for these genes is common in the general population, but our strategy here was to combine a population-based screen with a focused investigation of individuals with extreme lipid phenotypes (strongly atheroprotective *vs.* strongly atherogenic). Our hypothesis was that CNV encompassing the full length of a RCT gene would result in an increased or decreased amount of transcribed protein product directly proportional to the amount of copies present, thus impacting serum cholesterol levels. Further, we wished to investigate whether individuals with CNV in the central range would have normal lipid levels while those whose CNV was in the outermost edges of the range would have a dysregulated lipid metabolism leading to the extreme lipid profiles.

Our results in this study identified rare loss variants in 3 of the RCT genes. Out of 267 individuals and 16 genes studied with two different CNV assay procedures, *CETP* showed a loss in a single individual, and two genes (*ABCA1* and *APOA4*) showed apparent copy number losses with MLPA. The apparent loss of copy number seen for *APOA4* was determined to be due to a SNP in the ligation site of its MLPA probe while the apparent loss seen at *ABCA1* is suspected to be not genuine. The small standard deviation seen, along with the reproducibility of the significant loss of signal during additional MLPA runs, indicates that the loss for the *CETP* probe was valid. Coupled with the tight clustering around the normalized ratio of 1.0 for the non-outlying points of all of the RCT probes, these results strongly suggest that whole gene CNV is not present in the RCT genes at anything above very low levels, and is therefore not likely to be a major influence on lipid levels in either the normal population or those infected with HIV and receiving antiretroviral therapy.

These findings are consistent with previous reports of limited structural variation in the RCT genes, as presented in the Database of Genomic Variants \[[@CR53], [@CR57]\]. Within this database, deletions that included whole genes were observed for *CETP*. The *ABCA1* gene was observed to have a wide variety of insertions and deletions within its bounds, including five losses in the region of our MLPA probe, although none of them encompass the entire gene. All of these reported variants were extremely rare, with only a few individuals having the variant in studies containing several thousand participants. For those with higher frequencies, the study sizes were too small to conclude that a common variant was observed.

We also compared the ratios obtained with both CNV assays to gene expression data available for a subset of our samples. None of the genes for which we had available CNV data showed variation in expression level. This further suggests that it is unlikely that significant CNV is present in these genes that might affect expression.

Limitations {#Sec8}
-----------

Our study was designed to detect any gene-specific CNV in members of the RCT pathway that may impact levels of gene expression and subsequent enzymatic activity that therefore affect lipid levels and lead to dyslipidemia in members of our study cohort. Our study does have some limitations. As no prior survey of CNV in these genes had been attempted, the frequency of such variants was unknown and our study was exploratory. As such, it had limited statistical power to assess the impact of CNV between the atherogenic and atheroprotective groups. Also, the sizes of the atheroprotective (n = 23) and atheroprotective (n = 7) groups are not evenly matched, which would preclude more advanced statistical analysis were we to have found CNV in our samples, but the overall sample size of 319 individuals successfully typed is large enough to have detected any common variants and we can conclude that CNV of these genes is rare or absent. As we only designed one CNV probe set per gene it is also possible that variation within a gene could have been missed---for example, the *LPA* gene contains many kringle repeats that were not a focus of our study.

Our study was also limited by the type of clinical data available. In each biannual visit, serum cholesterol and triglyceride measurements are obtained from our study participants, and were used to define our atherogenic and atheroprotective groups. Other measurements, such as lipoprotein particle size and number, and HDL efflux capacity, have been shown to be stronger predictors of cardiovascular disease risk \[[@CR58], [@CR59]\], and would have been collected on subsequent visits had our initial study shown a role for CNV in this pathway. Our samples were also collected prior to the widespread use of the 2013 ACC/AHA guideline, and we therefore use the older NCEP ATP III panel, but our data are based on a sufficiently large sample size to overcome this issue.

Conclusions {#Sec9}
===========

In this study we were able to develop a MLPA assay capable of detecting CNV when it is present. Using this assay we have illustrated that whole gene CNV is present only at very low levels in the RCT genes, and is not a major factor in the development of HAART-associated dyslipidemia. Thus, other host genetic influences exist and need to be identified before we are able to understand fully the ways in which host, viral, and therapeutic environmental factors interact to determine the outcome of antiretroviral therapy in HIV-positive individuals.

Methods {#Sec10}
=======

Samples {#Sec11}
-------

Experimental samples were obtained from the Multicenter AIDS Cohort Study (MACS). The MACS is a multicenter (Baltimore, MD; Chicago, IL; Pittsburgh, PA; and Los Angeles, CA) ongoing prospective study, founded in 1984, of the natural and treated histories of HIV-1 infection in men who have sex with men. Participants attend clinics bi-annually for a physical exam and sample collection, and complete extensive questionnaires about their medical history, behavior changes, and overall quality of life. All samples were obtained from volunteer participants who had read and agreed to the consent policy implemented by the MACS for the protection of human subjects, and approved by the Institutional Review Board (IRB) at each MACS site (The University of Pittsburgh Institutional Review Board; The Johns Hopkins University Institutional Review Board; Northwestern University Institutional Review Board; and The University of California, Los Angeles Medical Institutional Review Board).

Samples (n = 366) were identified on the basis of serum lipid measures obtained in their 2005 visit. We used the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) \[[@CR54]\] to identify lipid levels associated with higher risk of heart disease (HDL-C \<40 mg/dL and/or LDL-C \>130 mg/dL) or with lower risk (HDL-C \>60 mg/dL and/or LDL-C \<100 mg/dL) \[[@CR60]\]. DNA was extracted from frozen peripheral blood mononuclear cell pellets using the Qiagen QIAamp DNA Blood Mini Kit, following the Blood and Body Fluid Spin Protocol. DNAs were stored at −20 °C.

We also obtained 4 DNA control samples (NA07048, NA10846, NA10861, and NS12911) from the Coriell Institute cell repository. Three of these individuals served as reference samples, as the CNV of their *DEFB103A* gene was already known \[[@CR61]--[@CR63]\]. We also used 5 DNA samples obtained from volunteer donors in our laboratory as additional controls.

Copy number variation detection by multiplex ligation-dependent probe amplification (MLPA) {#Sec12}
------------------------------------------------------------------------------------------

MLPA was performed using the MRC-Holland SALSA MLPA P300 Human DNA Reference-2 (Version: A1-0410) probemix kit, in conjunction with 16 custom probes for RCT pathway genes (Table [3](#Tab3){ref-type="table"}). Custom probes were designed following the manufacturer's criteria (Synthetic Probe Design v10-update 04-02-2009) utilizing the human genome 18 reference assembly and the Stonybrook MLPA design browser (<http://bioinform.arcan.stonybrook.edu/mlpa2/cgi-bin/mlpa.cgi>) \[[@CR64], [@CR65]\]. BLAST searches were used to verify probe specificity prior to synthesis (Integrated DNA Technologies, Coralville, IA, USA). Additional 5′phosphorylation of the right-hand probe oligo was performed in our laboratory (Additional file [2](#MOESM2){ref-type="media"}: Table S1).Table 3Reverse Cholesterol Transport (RCT) pathway genes selected for analysisGene nameSymbolChromo-someFunctionReferencesScavenger receptor class B, member 1SRBI12Plasma membrane receptor for HDL that mediates transfer of cholesterol to and from HDL\[[@CR33]\]Apolipoprotein C-IIIAPOC311Very low density lipoprotein that inhibits lipoprotein lipase and hepatic lipase delaying triglyceride-rich particle catabolism\[[@CR32]\]Apolipoprotein A-IAPOA111Major protein component of HDL and a cofactor of LCAT. Defects in APOA1 results in HDL deficiencies\[[@CR32], [@CR33]\]Apolipoprotein EAPOE19Main apoprotein of chylomicron and essential for catabolism of triglyceride-rich lipoprotein constituents\[[@CR32], [@CR33]\]Phospholipid Transfer ProteinPLTP20Lipid transfer protein that transfers phospholipids from triglyceride-rich lipoproteins to HDL\[[@CR33]\]Hepatic LipaseLIPC15Triglyceride hydrolase and ligand/bridging factor for receptor mediated lipoprotein uptake\[[@CR32], [@CR33]\]Lecithin-cholesterol AcyltransferaseLCAT16Extracellular cholesterol esterifying enzyme that esterifies cholesterol for transport\[[@CR32], [@CR33]\]Apolipoprotein A-IVAPOA411Potent activator of lecithin-cholesterol acyltransferase\[[@CR32]\]Lipoprotein LipaseLPL8Triglyceride hydrolase and ligand/bridging factor for receptor mediated lipoprotein uptake\[[@CR32], [@CR33]\]Endothelial LipaseLIPG18Regulates circulating levels of HDL and acts has phospholipase activity\[[@CR33]\]Low Density Lipoprotein ReceptorLDLR19Cell surface protein involved in receptor-mediated endocytosis of LDL\[[@CR32], [@CR33]\]Cholesteryl ester transfer proteinCETP16Transfers cholesteryl esters between lipoproteins\[[@CR32], [@CR33]\]Apolipoprotein A-VAPOA511Component of high density lipoprotein\[[@CR32]\]Apolipoprotein BAPOB2Main apolipoprotein of chylomicrons and low density lipoproteins\[[@CR32]\]ATP-binding cassette, sub-family A, member 1ABCA19Membrane associated protein that functions as a cholesterol efflux pump in the cellular lipid removal pathway\[[@CR32], [@CR33]\]Apolipoprotein C-IIAPOC219Plasma lipid-binding protein that activates lipoprotein lipase\[[@CR32]\]

MLPA reactions were performed following the standard 1 tube protocol (MDP-v001, update 17-06-2011) with an 18--19 h hybridization and amplification step using the new universal primers (released in June 2011). Fragment separation was performed at the University of Pittsburgh Genomics and Proteomics Core Laboratories.

Analysis of MLPA data {#Sec13}
---------------------

The Coffalyser.net software (<http://wiki.coffalyser.net>) was used to perform fragment and comparative analysis. Initially, no reference samples were indicated, and samples with average signal across all probes were selected as references for each of the four 96 sample runs. Fragment analysis was then performed for a second time with default settings. Samples with poor reference probe quality and reproducibility were removed before comparative analysis was performed for a second time. Final ratios and standard deviations were analyzed with the R statistical software package \[[@CR66]\] and the following modules: ggplot2 \[[@CR67]\], reshape \[[@CR68]\], and gridExtra \[[@CR69]\].

Copy number calling {#Sec14}
-------------------

For probes that lacked reference samples with known copy number levels, discrete copies were not calculated. Instead, the default ratio thresholds (0.7, 1.3), defined by MRC-Holland and based on a 2-copy reference sample (MLPA Results Interpretation---V02.2;11-02-2010) \[[@CR70]\], were used to identify individuals who exhibited a gain (\>1.3) or loss (\<0.7) of copy number. The interquartile range (IQR) of each probe was also compared to that of the reference probes to identify experimental probes with potential CNV that did not cross the default threshold. If a reference sample with a known discrete copy number was available for a given probe, the discrete copy number of the experimental samples was determined by cluster analysis of raw copy number calls \[[@CR71]\] (Additional file [1](#MOESM1){ref-type="media"}: Supplementary Methods; Additional file [2](#MOESM2){ref-type="media"}: Figure S1 and Table S2).

CNV confirmation assay {#Sec15}
----------------------

A NanoString nCounter custom CNV CodeSet was designed containing the 16 RCT genes analyzed in our MLPA assay, and used to type 267 of the experimental samples previously typed by MLPA. DNA was processed and analyzed using a NanoString Technologies nCounter system at the University of Pittsburgh Genomics and Proteomics Core Laboratories. The NanoString nSolver Analysis Software (v1.1) was used to generate normalized ratios from raw counts, with 34 of the original MLPA samples set as RCT references.

Gene expression analysis {#Sec16}
------------------------

Gene expression data were available for 127 of the samples studied by MLPA and NanoString. These were obtained from whole blood collected into PAXgene tubes, from which RNA was extracted using the PAXgene Blood RNA Kit IVD. Samples were quantified, processed, and analyzed using the Illumina Human HT-12 v.4 whole-genome expression array at the University of Pittsburgh Genomics and Proteomics Core Laboratories. Raw data was exported from Illumina Genome Studio and further data analysis was performed using the Bioconductor R modules lumi \[[@CR72]\] and ArrayQualityMetrics \[[@CR73]\].

Availability of supporting data {#Sec17}
-------------------------------

Data are held by the Center for Analysis and Management of the Multicenter AIDS Cohort Study (CAMACS). For access to the MACS data, please complete the collaboration concept sheet and identify the article for which the data were used. This form and instructions may be found at: <http://statepi.jhsph.edu/macs/forms.html>.

Additional files {#Sec18}
================

10.1186/s13104-015-1665-z  Supplementary Methods. File Format: PDF.10.1186/s13104-015-1665-z Supplemental Figures and Tables. **Figure S1.** Reproducible Typing of Rounded Whole Copy Number Calls depends on Distribution of Raw Copy Numbers around Whole Integer Values. **Figure S2.** Probes and reference samples demonstrating a range of CNV further Illustrate the rare nature of CNV in the RCT genes. **Table S1.** Custom MLPA Probe Specifics. **Table S2.** Accuracy of Copy Number Calls is Dependent on Method of Calling. File Format: PDF.
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